The State of Biosimilars in 2019
February 6, 2019
While still largely a new phenomenon, biosimilars are here to stay—and this year will only bring more of them to market.
Bryant Furlow
Will biosimilars deliver on expectations?
January 6, 2018
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Payers struggle to keep up with high rate of FDA drug approvals
October 20, 2017
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
Payers need access to pre-approval drug information
October 19, 2017
Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?
Survey: How payers use nonpayer generated data to make formulary decisions
October 19, 2017
External, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Meeting the ‘status quo’ with CMS Star Ratings equals regression
October 19, 2017
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
Payers can predict budget implications of high-cost drugs in the pipeline
October 19, 2017
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Highly specific indications dominate cancer drug pipeline
October 18, 2017
Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.
Specialty drug pipeline predictions: Seven key areas to watch
October 18, 2017
The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Monetary benefits from value-based diabetes plans take time
October 18, 2017
Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.
